Orforglipron
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Orforglipron is listed as metabolic / oral small-molecule glp-1 agonist.
- •Obesity
- •Type 2 Diabetes (investigational)
Regulatory status: Investigational (Eli Lilly, Phase 3 ATTAIN/ACHIEVE).
Structure & Properties
Compound: Orforglipron; also known as LY3502970.
Pharmacologic class: Metabolic / Oral Small-molecule GLP-1 Agonist.
Known delivery routes: Oral.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Non-peptide oral GLP-1 receptor agonist — preserves GLP-1 pharmacology without injection or food restrictions.
- •Oral convenience (no food/water restriction)
- •HbA1c reduction
- •Weight loss without injection
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Phase 2 weight loss ~14.7% at 36 wk.
Laboratory Research
Phase 2 weight loss ~14.7% at 36 wk
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Once daily oral, taken consistently — labels expected to specify fasted dosing window.
Potential interactions and combinations to avoid
- •Other GLP-1 agonists
- •MTC/MEN2
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •GI side effects
- •LFT elevations (monitor)
- •Heart rate increase
Contraindications
- •MTC / MEN-2 (class)
- •Pregnancy
- •Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
- •History of pancreatitis or unexplained elevated lipase/amylase
- •Gastroparesis, severe GERD, or chronic gastrointestinal motility disorder
- •History of symptomatic gallstones or biliary disease
- •Active eating disorder, malnutrition, or BMI already in the underweight range
- •Type 1 diabetes as monotherapy for glycemic control
- •Planned surgery/anesthesia without pre-procedure fasting adjustment (aspiration risk)
- •Proliferative diabetic retinopathy with rapid glycemic lowering
- •Severe renal impairment with ongoing dehydration or vomiting
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 12–45 mg/day (trial)
Frequency: Daily oral
Cycling: Continuous with titration.
Oral
Once daily — first non-peptide GLP-1 pill.
Tablet. Take at consistent time; label will specify fasting window.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Metformin
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Morning, on an empty stomach with water — wait 30 min before food.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
Orforglipron has no injection site — see the routes below.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous with titration.
Timing & Interactions
- ·Other GLP-1 agonists
- ·MTC/MEN2
- ·Metformin
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Orforglipron and sync them to Vial Lab.
Benefits
- ·Oral convenience (no food/water restriction)
- ·HbA1c reduction
- ·Weight loss without injection
Risks
- ·GI side effects
- ·LFT elevations (monitor)
- ·Heart rate increase
Contraindications
- ·MTC / MEN-2 (class)
- ·Pregnancy
- ·Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
- ·History of pancreatitis or unexplained elevated lipase/amylase
- ·Gastroparesis, severe GERD, or chronic gastrointestinal motility disorder
- ·History of symptomatic gallstones or biliary disease
- ·Active eating disorder, malnutrition, or BMI already in the underweight range
- ·Type 1 diabetes as monotherapy for glycemic control
- ·Planned surgery/anesthesia without pre-procedure fasting adjustment (aspiration risk)
- ·Proliferative diabetic retinopathy with rapid glycemic lowering
- ·Severe renal impairment with ongoing dehydration or vomiting
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Investigational (Eli Lilly, Phase 3 ATTAIN/ACHIEVE)
Veterinary Use (Pets)
No established veterinary protocol for Orforglipron. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.